U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07180771) titled 'A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.' on Sept. 04.
Brief Summary: The objective of this phase II study is to evaluate the efficacy and safety of BR101801 in patients with peripheral T-cell lymphoma(PTCL).
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Peripheral T Cell Lymphoma
Intervention:
DRUG: BR101801
Patients will receive 200mg capsules (100mg+100mg)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Boryung Pharmaceutical Co., Ltd
Published by HT Digital Content Services with permission from Health Daily Digest....